• Consensus Rating: Moderate Buy
  • Consensus Price Target: $60.00
  • Forecasted Upside: 30.26%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.08 (0.17%)

This chart shows the closing price for SNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sanofi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNY

Analyst Price Target is $60.00
▲ +30.26% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $60.00, with a high forecast of $60.00 and a low forecast of $60.00. The average price target represents a 30.26% upside from the last price of $46.06.

This chart shows the closing price for SNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Sanofi. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2023JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
10/30/2023Stifel NicolausDowngradeBuy ➝ HoldLow
9/5/2023Berenberg BankUpgradeHold ➝ BuyLow
7/14/2023HSBCInitiated CoverageBuyLow
4/28/2023Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
3/27/2023ArgusBoost TargetBuy$55.00 ➝ $60.00Low
3/27/2023BarclaysUpgradeEqual Weight ➝ OverweightLow
12/16/2022The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyLow
12/13/2022Morgan StanleyReiterated RatingOverweightLow
10/14/2022BarclaysLower TargetEqual Weight ➝ Equal Weight€105.00 ➝ €85.00Low
9/8/2022Morgan StanleyLower Target€112.00 ➝ €93.00Low
9/7/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€90.00 ➝ €85.00Low
8/24/2022Kepler Capital MarketsDowngradeBuy ➝ Hold€120.00 ➝ €89.00Low
8/24/2022CheuvreuxDowngradeBuy ➝ HoldLow
8/12/2022Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
8/9/2022UBS GroupDowngradeBuy ➝ NeutralLow
8/1/2022JPMorgan Chase & Co.Boost Target€105.00 ➝ €115.00Low
7/29/2022Deutsche Bank AktiengesellschaftBoost TargetSell ➝ Sell€85.00 ➝ €90.00Low
7/22/2022Credit Suisse GroupBoost TargetOutperform ➝ Outperform€105.00 ➝ €110.00Low
6/7/2022UBS GroupBoost TargetBuy ➝ Buy€118.00 ➝ €119.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperformMedium
5/2/2022GuggenheimBoost Target€121.00 ➝ €127.00Low
4/22/2022Morgan StanleyBoost Target€110.00 ➝ €112.00Low
4/14/2022BarclaysBoost Target€90.00 ➝ €105.00Low
4/8/2022UBS GroupLower TargetBuy ➝ Buy€122.00 ➝ €121.00Low
3/28/2022Morgan StanleyBoost Target€108.00 ➝ €110.00Medium
3/28/2022Credit Suisse GroupBoost Target€96.00 ➝ €105.00Low
3/28/2022Deutsche Bank AktiengesellschaftBoost Target€80.00 ➝ €85.00Low
2/28/2022Stifel NicolausInitiated CoverageBuyLow
1/25/2022Liberum CapitalUpgradeHold ➝ BuyMedium
11/1/2021HSBCUpgradeHold ➝ BuyLow
10/14/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
9/27/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
8/12/2021UBS GroupReiterated RatingBuyLow
8/6/2021Morgan StanleyReiterated RatingOverweightMedium
7/30/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
4/29/2021BarclaysReiterated RatingEqual WeightLow
4/6/2021BarclaysReiterated RatingEqual WeightLow
2/10/2021Morgan StanleyReiterated RatingOverweightLow
1/19/2021UBS GroupReiterated RatingBuyLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageSellLow
1/8/2021Morgan StanleyReiterated RatingOverweightLow
11/3/2020Morgan StanleyReiterated RatingOverweightMedium
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/4/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
9/29/2020Berenberg BankInitiated CoverageHoldLow
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
8/18/2020SVB LeerinkDowngradeMarket PerformLow
7/31/2020JPMorgan Chase & Co.Reiterated RatingOverweightMedium
6/9/2020Morgan StanleyReiterated RatingOverweightMedium
5/26/2020UBS GroupReiterated RatingBuyMedium
4/28/2020BarclaysReiterated RatingEqual WeightMedium
4/21/2020Morgan StanleyReiterated RatingOverweightMedium
3/17/2020BarclaysUpgradeUnderweight ➝ Equal WeightHigh
3/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
2/19/2020ArgusBoost TargetBuy$52.00 ➝ $56.00Low
2/11/2020SVB LeerinkInitiated CoverageMarket Perform$58.00Low
2/7/2020DZ BankReiterated RatingNeutralLow
1/22/2020Liberum CapitalDowngradeBuy ➝ HoldLow
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
12/6/2019BarclaysDowngradeEqual Weight ➝ UnderweightLow
11/13/2019ArgusReiterated RatingBuy$50.00 ➝ $52.00Low
10/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/23/2019GuggenheimUpgradeNeutral ➝ BuyLow
9/20/2019Morgan StanleyUpgradeEqual ➝ Equal WeightMedium
9/3/2019Sanford C. BernsteinInitiated CoverageOutperform$52.00Low
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
8/14/2019UBS GroupUpgradeNeutral ➝ BuyHigh
8/6/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/28/2019HC WainwrightReiterated RatingBuyLow
1/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralMedium
12/14/2018Morgan StanleyInitiated CoverageEqual WeightLow
12/11/2018Jefferies Financial GroupUpgradeHold ➝ BuyLow
(Data available from 12/7/2018 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 22 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
  • 20 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 16 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 24 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 9 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 13 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sanofi logo
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More

Today's Range

Now: $46.06
Low: $45.36
High: $46.19

50 Day Range

MA: $49.08
Low: $43.13
High: $54.79

52 Week Range

Now: $46.06
Low: $42.63
High: $57.82


1,947,014 shs

Average Volume

1,735,594 shs

Market Capitalization

$116.51 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Sanofi?

The following Wall Street sell-side analysts have issued stock ratings on Sanofi in the last twelve months: Argus, Barclays PLC, Berenberg Bank, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for SNY.

What is the current price target for Sanofi?

1 Wall Street analysts have set twelve-month price targets for Sanofi in the last year. Their average twelve-month price target is $60.00, suggesting a possible upside of 31.7%. Argus has the highest price target set, predicting SNY will reach $60.00 in the next twelve months. Argus has the lowest price target set, forecasting a price of $60.00 for Sanofi in the next year.
View the latest price targets for SNY.

What is the current consensus analyst rating for Sanofi?

Sanofi currently has 1 sell rating, 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SNY.

What other companies compete with Sanofi?

How do I contact Sanofi's investor relations team?

Sanofi's physical mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company's listed phone number is (315) 377-4000 and its investor relations email address is [email protected]. The official website for Sanofi is www.sanofi.com. Learn More about contacing Sanofi investor relations.